Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis

BACKGROUND: Rheumatoid arthritis (RA) is a common chronic condition with substantial morbidity that can now be treated with disease-modifying biologic agents that target tumor necrosis factor (TNF) or related mechanisms. The anti-TNF biologic agents are available in either intravenous (IV) or subcut...

Descripción completa

Detalles Bibliográficos
Autores principales: Stavrakas, Spyros, Wong, Bruce, Cifaldi, Mary A., Roy, Sanjoy, Skonieczny, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438202/
https://www.ncbi.nlm.nih.gov/pubmed/21534642
http://dx.doi.org/10.18553/jmcp.2011.17.4.313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438202/
https://www.ncbi.nlm.nih.gov/pubmed/21534642
http://dx.doi.org/10.18553/jmcp.2011.17.4.313

Ejemplares similares